Affiliation:
1. National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia
2. Faculty of Biology, Lomonosov Moscow State University, Leninskie Gory, 119234 Moscow, Russia
Abstract
Major depression is one of the most prevalent mental disorders, causing significant human suffering and socioeconomic loss. Since conventional antidepressants are not sufficiently effective, there is an urgent need to develop new antidepressant medications. Despite marked advances in the neurobiology of depression, the etiology and pathophysiology of this disease remain poorly understood. Classical and newer hypotheses of depression suggest that an imbalance of brain monoamines, dysregulation of the hypothalamic-pituitary-adrenal axis (HPAA) and immune system, or impaired hippocampal neurogenesis and neurotrophic factors pathways are cause of depression. It is assumed that conventional antidepressants improve these closely related disturbances. The purpose of this review was to discuss the possibility of affecting these disturbances by targeting the melanocortin system, which includes adrenocorticotropic hormone-activated receptors and their peptide ligands (melanocortins). The melanocortin system is involved in the regulation of various processes in the brain and periphery. Melanocortins, including peripherally administered non-corticotropic agonists, regulate HPAA activity, exhibit anti-inflammatory effects, stimulate the levels of neurotrophic factors, and enhance hippocampal neurogenesis and neurotransmission. Therefore, endogenous melanocortins and their analogs are able to complexly affect the functioning of those body’s systems that are closely related to depression and the effects of antidepressants, thereby demonstrating a promising antidepressant potential.
Funder
Russian Science Foundation
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference363 articles.
1. World Health Organization (2023, February 28). Depression. Available online: https://www.who.int/news-room/fact-sheets/detail/depression.
2. Moitra, M., Santomauro, D., Collins, P.Y., Vos, T., Whiteford, H., Saxena, S., and Ferrari, A.J. (2022). The Global Gap in Treatment Coverage for Major Depressive Disorder in 84 Countries from 2000–2019: A Systematic Review and Bayesian Meta-Regression Analysis. PLoS Med., 19.
3. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association.
4. van Loo, H.M., de Jonge, P., Romeijn, J.-W., Kessler, R.C., and Schoevers, R.A. (2012). Data-Driven Subtypes of Major Depressive Disorder: A Systematic Review. BMC Med., 10.
5. Genetic Epidemiology of Major Depression: Review and Meta-Analysis;Sullivan;Am. J. Psychiatry,2000
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献